Home » Newsletters » BioWorld Science

BioWorld Science

June 10, 2014

View Archived Issues

PD-404182 evaluated as an anti-HIV and anti-HSV microbicidal candidate

Autifony Therapeutics awarded grant to support phase IIa study of AUT-00063 for tinnitus

Novel XIAP inhibitors developed by Bristol-Myers Squibb and Ensemble Therapeutics

Nerviano Medical Sciences prepares new RET inhibitors

Pfizer presents novel dopamine D1 receptor agonists

OMP-59R5 plus etoposide is well tolerated in SCLC patients

PENELOPE data: pertuzumab + topotecan + paclitaxel in ovarian cancer

First-in-human results for anti-IGF-I/II antibody BI-836845

COMBI-d: first phase III trial of dabrafenib + trametinib in metastatic melanoma

Researchers patent novel tuberculosis vaccines

LG Life Sciences discloses new GPR40 agonists

Novel agents for HIV infection disclosed by Belgian team

Complexa completes series B financing to support development of CXA-10

KineMed and Pfizer extend research collaboration

Phase II study of fruquintinib initiated in non-small cell lung cancer

Ventana Medical Systems and MedImmune collaborate on PD-L1 assay

Critical Outcome Technologies completes financing round to support lead candidate

Curis re-initiates patient dosing in monotherapy trial of CUDC-427

National Institute of Mental Health recruits participants in study of radioligand [11C]ER-176

Immune Design confirms first patient treated in phase I clinical trial of LV-305

Agalimmune receives milestone payment triggered by phase I trials of Alphaject technology

Revive Therapeutics submits pre-IND package to the FDA for REV-002

FDA grants fast track designation to Epidiolex for Dravet syndrome

Pradaxa approved in E.U. for prevention of deep vein thrombosis and pulmonary embolism

Valeant's Jublia approved in U.S. for onychomycosis

FDA approves Eloctate for hemophilia A

Merck & Co. set to acquire Idenix Pharmaceuticals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...